risedronate an risedronate sodium 30mg tablet blister pack
amneal pharma australia pty ltd - risedronate sodium hemipentahydrate, quantity: 34.43 mg (equivalent: risedronate sodium, qty 30 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; magnesium stearate; hypromellose; crospovidone; macrogol 400; lactose monohydrate; titanium dioxide - treatment of paget?s disease of bone
auro-risedronate 35 risedronate sodium 35mg tablet blister pack
arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 40.17 mg (equivalent: risedronate sodium, qty 35 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; lactose monohydrate; magnesium stearate; hyprolose; titanium dioxide; macrogol 8000; hypromellose; colloidal anhydrous silica; iron oxide yellow; iron oxide red; macrogol 400 - ? treatment of osteoporosis,? treatment of glucocorticoid-induced osteoporosis,? preservation of bone mineral density in patients on long term corticosteroid therapy
auro-risedronate 30 risedronate sodium 30mg tablet blister pack
arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 34.43 mg (equivalent: risedronate sodium, qty 30 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; hyprolose; crospovidone; microcrystalline cellulose; magnesium stearate; hypromellose; macrogol 400; titanium dioxide - treatment of paget?s disease of bone
auro-risedronate 5 risedronate sodium 5mg tablet blister pack
arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 5.74 mg (equivalent: risedronate sodium, qty 5 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; crospovidone; hyprolose; titanium dioxide; hypromellose; macrogol 8000; colloidal anhydrous silica; iron oxide yellow; macrogol 400 - ? treatment of osteoporosis,? treatment of glucocorticoid-induced osteoporosis,? preservation of bone mineral density in patients on long term corticosteroid therapy
arx-letrozole letrozole 2.5 mg film-coated tablet blister pack
cipla australia pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; microcrystalline cellulose; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 400 - for the treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.
apo-tibolone tibolone 2.5 mg tablet blister pack
arrotex pharmaceuticals pty ltd -
tibolone, quantity: 2.5 mg -
tablet, uncoated - excipient ingredients: pregelatinised potato starch; ascorbyl palmitate; magnesium stearate; lactose monohydrate; lactose - ? short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women. ? second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, <
exemestane gh exemestane 25mg tablet blister pack
generic health pty ltd - exemestane, quantity: 25 mg - tablet, film coated - excipient ingredients: crospovidone; sodium starch glycollate type a; hypromellose; magnesium stearate; mannitol; microcrystalline cellulose; colloidal anhydrous silica; polysorbate 80; titanium dioxide; macrogol 400 - exemestane is indicated for the sequential adjuvant treatment of estrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy. . exemestane is indicated for the treatment of estrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-estrogen therapy.
femolet letrozole 2.5 mg film-coated tablet blister pack
alphapharm pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; maize starch; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 8000; hypromellose; triacetin; iron oxide yellow; iron oxide red; quinoline yellow aluminium lake; polydextrose - for the treatment of postmenopausal women with hormone receptor positive breast cancer. the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.
xyvion tibolone 2.5mg tablet blister pack
organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; ascorbyl palmitate; potato starch; lactose monohydrate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, xyvion should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). xyvion should only be continued for as long as the benefit outweighs the risks.
livial tibolone 2.5mg tablet blister pack
organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; potato starch; lactose monohydrate; ascorbyl palmitate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, livial should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). livial should only be continued for as long as the benefit outweighs the risks.